Stable coronary artery disease - medical treatment

Area of Science:

• Cardiology
• Internal Medicine
• Pharmacology

Background:

• Optimal medical therapy is crucial for improving prognosis and reducing angina symptoms.
• Despite advances in percutaneous coronary interventions (PCI) and standard medications, some patients remain symptomatic.
• Secondary prevention, managing comorbidities, and controlling risk factors are vital components of care.

Purpose of the Study:

• To emphasize the importance of comprehensive medical therapy for angina pectoris.
• To highlight the underutilization of certain antianginal drugs in the era of PCI.
• To advocate for improved medical management to potentially avoid secondary coronary interventions.

Main Methods:

• Review of current treatment strategies for angina pectoris.
• Analysis of the role of various drug classes, including calcium antagonists, nitrates, metabolic agents, and novel antianginal drugs.
• Consideration of evidence from trials such as Courage and BARI.

Main Results:

• Percutaneous coronary interventions (PCI) and standard medical treatments (beta-blockers, ACE-inhibitors, statins, antiplatelets) do not fully resolve symptoms in all patients.
• Other drug classes like calcium antagonists, long-acting nitrates, metabolic agents, and novel antianginal drugs are underutilized.
• Proper medical management of angina pectoris can potentially reduce the need for secondary coronary interventions.

Conclusions:

• Optimal medical therapy remains a cornerstone in managing angina pectoris, even in the era of PCI.
• Increased attention to a broader range of antianginal medications is warranted.
• Effective medical treatment can improve patient outcomes and potentially decrease the necessity for invasive procedures.